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Phase I trial of vorinostat and doxorubicin in solid tumours:
histone deacetylase 2 expression as a predictive marker
PNMunster*,1, D Marchion2, S Thomas1, M Egorin3, S Minton2, G Springett2, J-H Lee2, G Simon2, A Chiappori2,
D Sullivan2 and A Daud1
1Division of Hematology and Oncology, University of California, San Francisco, CA 94143, USA; 2H. Lee Moff itt Cancer Center and Research Institute,
Tampa, FL 33647, USA; 3Department of Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
BACKGROUND: Histone deacetylase inhibitors (HDACi) can sensitise cancer cells to topoisomerase inhibitors by increasing their access
and binding to DNA.
METHODS: This phase I trial was designed to determine the toxicity profile, tolerability, and recommended phase II dose of escalating
doses of the HDACi vorinostat, with weekly doxorubicin.
RESULTS: In total, 32 patients were treated; vorinostat was dosed at 400, 600, 800, or 1000mg day1 on days 1–3, followed by
doxorubicin (20mgm2) on day 3 for 3 of 4 weeks. Maximal tolerated dose was determined to be 800mg day1 of vorinostat.
Dose-limiting toxicities were grade 3 nausea/vomiting (two out of six) and fatigue (one out of six) at 1000mg day1. Non-dose-
limiting grade 3/4 toxicities included haematological toxicity and venous thromboembolism. Antitumor activity in 24 evaluable
patients included two partial responses (breast and prostate cancer). Two patients with melanoma had stable disease forX8 months.
Histone hyperacetylation changes in peripheral blood mononuclear and tumour cells were comparable. Histone hyperacetylation
seemed to correlate with pre-treatment HDAC2 expression.
CONCLUSION: These findings suggest that vorinostat can be combined with weekly doxorubicin in this schedule at a dose of
800mg day1. The HDAC2 expression may be a marker predictive of HDAC inhibition. Antitumor activity of this regimen in breast
cancer, prostate cancer, and melanoma seems interesting.
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Histone deacetylase (HDAC) inhibitors, agents that modulate
chromatin plasticity, are undergoing extensive clinical and non-
clinical evaluation. Acetylation and deacetylation of histones or
non-histone protein targets are directly or indirectly associated
with tumour evolution and tumour progression (Grunstein, 1997;
Marks et al, 2001). The HDAC inhibitors have been studied in a
wide range of cancers either alone or in combination with other
anticancer agents. The first HDAC inhibitor to be approved was
vorinostat (Zolinza, Merck, Whitehouse Station, NJ, USA), a
hydroxamic acid-type HDAC inhibitor, for cutaneous T-cell
lymphoma (Kelly et al, 2003, 2005; O’Connor et al, 2006; Duvic
et al, 2007).
The HDAC inhibitors can potentiate the cytotoxicity of
anthracycline-type topoisomerase (topo) II inhibitors such as
doxorubicin, epirubicin, and mitoxanthrone (Tsai et al, 2000;
Johnson et al, 2001; Kurz et al, 2001; Marchion et al, 2005a, b, c;
Munster et al, 2007). Topo II inhibitors induce DNA strand breaks
by binding to DNA, stabilizing the topo II-DNA complex, and
inhibiting the re-ligation of DNA strands during replication.
HDAC inhibitor-induced chromatin decondensation increases the
binding of topo II inhibitors to their DNA substrate (Marchion
et al, 2005a, b, c). Xenograft studies have suggested that synergy
between HDAC and topo II inhibitors is dose-dependent and
requires exposure to the HDAC inhibitor for at least 48 h before the
topo II inhibitor (Johnson et al, 2001; Kurz et al, 2001; Marchion
et al, 2004). On the basis of these and other preclinical data, a
phase I trial with the HDAC inhibitor valproic acid (VPA) and
epirubicin was performed with promising results (Munster et al,
2007, 2009). There are clear limitations, however, to VPA: it has
low potency and significant neurological toxicity. We initiated this
study, therefore, to determine whether the potency and low
toxicity of the hydroxamic acid derivative vorinostat could be
exploited in combination with weekly doxorubicin. As the subtype
specificity of the HDAC target of vorinostat is not known, we
undertook extensive sampling of tumour cells and peripheral
blood mononuclear cells (PBMCs) to determine whether the
response could be predicted based on expression of specific HDAC
subtype.
MATERIALS AND METHODS
Trial design
This trial was approved by the Protocol Review Committee,
the Institutional Review Board at the Moffitt Cancer Center, and
the Cancer Therapy Evaluation Program (the study sponsor)
(Clinicaltrials.gov identifier NCT00331955). Vorinostat was
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administered orally on days 1, 2, and 3 with a planned vorinostat
dose escalation of 400, 600, 800, and 1000mg given in two divided
daily doses. Fixed doses of doxorubicin 20mgm2 (Adriamycin,
Pfizer, New York, NY, USA) were infused on day 3, 4 h after the last
vorinostat dose. Treatment was given weekly 3 out of 4 weeks; a
cycle consisted of 4 weeks. A maximum of six cycles (24 weeks) of
doxorubicin was allowed. In patients with demonstrated benefit,
doxorubicin was then stopped and patients were treated with
vorinostat only. The dose escalation followed a conventional dose
escalation scheme. In the absence of dose-limiting toxicities
(DLTs), cohorts were limited to three evaluable patients.
Patients
Eligible patients (age X18 years) had to have histologically
confirmed advanced solid tumour malignancies with an ECOG
performance status of 0–2 and adequate organ function (haemo-
globin 49.0 g per 100ml, white blood cell 43000 cells per mm3,
ANC 41500 cells per mm3, platelets 4100 000 cells per mm3,
creatinine p2mg per 100ml, bilirubin p1.5mg per 100ml, and
liver enzymes within 1.5 the upper level of institutional normal).
Patients with earlier anthracycline exposure, an ejection fraction of
o50% by multigated acquisition scan (MUGA) or echocardio-
gram, a history of long QT syndrome, or corrected QTc (QTc)
prolongations 4470ms at baseline were excluded.
Treatment and toxicity assessment
Baseline safety and toxicity evaluations included history and
physical examination, 12-lead ECG, and complete blood count with
differential, metabolic, hepatic, and renal function assessments.
These tests were repeated weekly during the first cycle and then
every 4 weeks in asymptomatic patients. Cardiac function was
assessed by MUGA or echocardiogram every two cycles. A 12-lead
ECG was performed before vorinostat treatment and on day 3 in
cycle 1. Day 3 ECGs in subsequent cycles were only performed if
the day 1 ECG showed any abnormalities or prolongations of the
QT interval. Tumour assessment by computer tomography, bone
scan, or MRI scan was performed at baseline and repeated after
every two cycles (8 weeks). Toxicities were captured in all patients
and graded by the Common Terminology Criteria for Adverse
Events (CTCAE v3). The DLTs were defined in cycle 1 as any grade
X3 non-haematological toxicities; grade 3 thrombocytopenia
lasting for 47 days or associated with bleeding; or any grade 4
haematological toxicity, with the exception of grade 4 neutropenia
or leucopenia for o8 days. Furthermore, any grade 2 toxicity that
prevented dose delivery in cycle 1 was considered dose limiting.
Patients in the dose escalation cohorts who did not complete the
first cycle and were not evaluable for toxicity had to be replaced.
Toxicities were captured in all patients who received at least one
dose of vorinostat; however, patients receiving less than one full
cycle of treatment and who were not evaluable for DLTs were
replaced.
Patients were considered evaluable for response if they had at
least two cycles of treatment or were taken off study early for
progression. Tumour response was graded by the response
evaluation criteria in solid tumours (RECIST) (Therasse et al,
2000). The correlation between variables was tested for statistical
significance using Spearman’s correlation coefficients with two-
sided P-values at a 0.05 significance level (SAS version 9.1, SAS
Institute, Inc., Cary, NC, USA). Spearman’s correlation coefficient
methods were used to estimate correlations between two variables
and to perform the test of significance of the estimated correlation.
Pharmacokinetic studies
Limited assessment of vorinostat plasma levels was obtained with
high-performance liquid chromatography (HPLC) at time of
tumour biopsies immediately before doxorubicin infusion
(time 0) and 2 and 48 h after doxorubicin infusion. A total of
5ml whole blood from a peripheral vein were collected in a Red
Top Vacutainer tube and refrigerated at 41C. The clotted samples
were centrifuged at 2000 g for 15min at 41C and stored at 701C.
All pharmacokinetic samples were analysed by Dr M Egorin
(University of Pittsburgh) by HPLC methods as previously
described (Parise et al, 2006).
Correlative studies
The PBMCs were isolated with Ficoll centrifugation (Ficoll-Paque,
GE HealthCare, Uppsala, Sweden) and adhered to glass slides using
cytospin funnels or collected in freezing media in liquid nitrogen
for western blot analysis. Tumour tissue was obtained by fine
needle aspirations of skin and subcutaneous lesions or core
biopsies of deeper structures under image guidance. The PBMC
and tumour samples were rapidly fixed with 5–95% acetic acid in
ethyl alcohol for 1min. Pre- and post-treatment slides were stained
with either anti-acetylated histone H3 or H4 (Upstate Biotechnology,
Lake Placid, NY, USA; polyclonal, 1 : 200), HDAC2 (Upstate
Biotechnology; monoclonal), HDAC6 (Abcam, Cambridge, MA,
USA; polyclonal, 1 : 200), topo IIa, topo IIb, and heterochromatin
protein 1 (HP-1) (all Upstate Biotechnology; polyclonal 1 : 200).
Slides were simultaneously counterstained with anti-pan histone 3
(Upstate Biotechnology; polyclonal, or BD Biosciences, San Jose,
CA, USA; monoclonal, 1 : 200) for 1 h. Respective proteins were
then developed with anti-rabbit Alexa-Fluor 546 and anti-mouse
Alexa-Fluor 488 (Molecular Probes, Eugene, OR, USA) and
bisbenzimide (0.5mgml1) for 1 h. All pre- and post-treatment
PBMC and tumour samples were evaluated by immunofluores-
cence confocal microscopy. Resultant images were analysed as
previously described (Marchion et al, 2005a, c; Munster et al,
2009). All PBMC samples were processed for western blot analysis,
and membranes were probed with the respective antibodies as
outlined for immunofluorescence staining: anti-acetylated histone
H4 or H3, topo IIa, topo IIb, HP-1, HDAC2, and HDAC6 (all rabbit
polyclonal, Upstate Biotechnology). Pre- and post-vorinostat pan
H3 expression served as internal control.
RESULTS
Treatments and toxicity
In total, 32 patients received at least one dose of study treatment.
A total of 30 patients completed at least one cycle of treatment, but
two patients in the first cohort could not be evaluated for toxicity
and were replaced: one patient required blood transfusion for
bleeding of a pre-existing wound and a second patient was found
to have brain metastases on day 8. Two patients at the maximally
administered dose of 1000mg vorinostat and one patient at the
dose expansion cohort (800mg) withdrew consent due to side-
effects after one cycle. Patient demographics and tumour
characteristics for all 32 patients are shown in Table 1. Overall,
24 patients completed at least two cycles of treatment and were
evaluable for response.
DLTs and serious adverse events
The first DLT was observed in the 800-mg cohort (Table 2).
A breast cancer patient with extensive bone marrow involvement
and multiple earlier cytotoxic therapies experienced grade 3
thrombocytopenia, which required protocol prespecified dose
modification. No further platelet-related DLTs were observed
during the first cycle of the study in any other patient, but two
more patients had grade 3 thrombocytopenia at the 800 and
1000mg vorinostat doses in subsequent cycles. At the maximally
administered dose of 1000mg day1, two patients experienced
Vorinostat–doxorubicin in solid tumours
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DLTs: one patient had grade 3 fatigue (one out of six) and one
patient had grade 2 nausea/vomiting in week 1 and week 2 despite
optimal supportive care that prevented continued treatment (one
out of six). Both DLTs resolved after treatment interruption, but
both patients withdrew consent (Table 2). At the dose expansion
cohort, one patient (1 out of 12) experienced a rise in the liver
enzymes, resulting in grade 3 toxicity. Vorinostat was reduced to
600mg daily for 3 days, and the patient did not experience further
changes in liver function during the first cycle. The patient
withdrew consent after 4 weeks for personal reasons. All together,
18 patients were treated with 800mg daily for 3 days and 2 patients
experienced DLTs. All four of the DLTs observed in the study
occurred in female patients.
Haematological toxicities
Non-dose-limiting grades 3 and 4 neutropenia was seen in 8 out of
32 patients (25%) (Table 3). Grade 3 thrombocytopenia occurred
in 3 out of 32 (9%) patients, including the patient with grade 3
thrombocytopenia meeting the DLT criteria. Treatment-related
anaemia was observed in one (3%) patient.
Non-haematological toxicities
As described above, DLTs included 2 out of 18 patients on the
800mg daily dose and 2 out of 6 at the 1000mg total daily dose of
vorinostat, given on days 1–3 of every week for 3 or 4 weeks
followed by doxorubicin. In addition to the observed DLTs, a
major toxicity was thromboembolic events occurring in 4 out of 32
patients (13%). These presented mainly as asymptomatic unilateral
or bilateral pulmonary emboli diagnosed on restaging images.
Although the temporary association with the study renders the
pulmonary emboli likely study drug related, a clear attribution to
either vorinostat, doxorubicin, or the combination cannot be
attained in the absence of a control arm without vorinostat. A
more precise attribution must be sought in future randomized
studies. Other grade 3 and 4 toxicities observed in study but after
the DLT period are depicted by cohort in Table 3. Predominant
grade 2 toxicities included fatigue in 17 out of 32 (53%), anorexia
in 15 out of 32 (47%), nausea/vomiting in 6 out of 32 (19%),
diarrhoea in 5 out of 32 (16%), alopecia in 8 out of 32 (25%),
hyperglycaemia in 3 out of 32 (9%), and somnolence in 1 out of 32
(3%) patients.
Cardiac toxicities
Although this protocol was not designed to determine cardiac
toxicities of vorinostat, limited cardiac evaluations were performed
for safety. All patients were followed with MUGA scans or
echocardiograms obtained every 8 weeks while on study. The
median ejection fraction at baseline was 61.5% (95% confidence
interval 60.1–62.8%). A median change of þ 2% (95% confidence
interval 0.7–3.3%) was observed over the course of the study for
all patients, and no grade 2 or higher changes in left ventricular
ejection fractions were observed in individual patients. On the
basis of reports of prolongations in QTc intervals seen in studies
Table 2 Treatment and responses
Total daily
vorinostat dose
(mg day1)
Single dose,
every 12 h 6
Doxorubicin,
mgm2 (day 3)
No. of patients
(N¼ 32)
No. of dose-limiting toxicities
(evaluable: N¼ 30)
Best response (evaluable: N¼ 24)
(partial response and stable disease
X12 weeks)
Dose escalation
400 200 20 5 (3 evaluable) PR: 8 months (breast)
600 300 20 3 PR: 8 months (prostate)
SD: 8 months (melanoma)
800 400 20 3+3 Thrombocytopenia (1/6) SD: X4 months (breast)
1000 500 20 3+3 Fatigue (1/6)
Nausea/vomiting (1/6)
SD: 8 months (melanoma)
SD (prostate)a
Dose expansion
800 400 20 12 Elevated liver enzymes (1/12) SD: X4 months (oesophageal)
Abbreviations: PR¼ partial response; SD¼ stable disease. aPatient withdrew consent after two cycles but remained stable.
Table 1 Patient characteristics (n¼ 32)
Gender
Female 17 (53%)
Male 15 (47%)
Age, years
Median (range) 53 (24–83)
X65 years (%) 7 (22)
Mean height, cm (range) 170 (156–187)
Female 164 (156–172)
Male 178 (170–187)
Mean weight, kg 79 (48–127)
Female (range; BMI) 75 (48–127; 28.1)
Male (range; BMI) 84 (68–100; 26.5)
Race/ethnicity
Caucasian 28 (88%)
African American 2 (6%)
Hispanic 2 (6%)
Tumour histology
Melanoma 6 (19%)
Breast 5 (16%)
Lung cancer 6 (19%)
Sarcoma 3 (9%)
Colon 2 (6%)
Prostate 2 (6%)
Oesophageal cancer 3 (9%)
Other (pancreatic, endometrial, neuroendocrine,
renal cell, bladder carcinoma)
5 (16%)
ECOG performance status
0 26 (81%)
1 6 (19%)
No. of earlier systemic metastatic regimens, median (range) 2 (0–6)
No. of cytotoxic agents, median (range) 1 (0–4)
No. of targeted, hormonal or immunotherapy,
median (range)
1 (0–6)
No. of patients with earlier radiation therapy (%) 11 (34%)
Abbreviation: BMI¼ body mass index.
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with this and other HDAC inhibitors, patients were screened for
long QTc intervals and all patients had an ECG on days 1 and 3 in
cycle 1. Further ECGs were obtained only on day 1 of each cycle,
but not on day 3 unless the QTc interval on day 1 was 4450ms.
One patient treated in the 1000mg vorinostat cohort and two
patients in the 800mg cohort experienced a grade 2 QTc
prolongation on day 3. A grade 2 QTc (475ms) was observed in
a fourth patient on day 1 of cycle 2, which persisted through day 3
(481ms). No intervention other than electrolyte replenishment was
needed in these patients.
Response
Patients experiencing clinical or radiological tumour progression
before completion of two cycles were included in the evaluation
and considered ‘progression’ (Table 2). Overall, 8 of 32 patients
were not evaluable, several patients withdrew consent after one
cycle, and one patient presented with brain metastases on day 8 of
cycle 1 and received only 1 week of treatment. Of 24 evaluable
patients, confirmed partial responses by radiological RECIST or by
prostate-specific antigen assessment were seen in 2 out of 24 (8%)
patients lasting for 8 months. Two patients with melanoma met the
criteria for stable disease and minor response for 8 months. After
receiving the prespecified maximum of six cycles of doxorubicin,
all of the four patients with either a response or clinical benefit
for more than 6 months progressed on vorinostat alone after
doxorubicin was stopped, suggesting a benefit from the combina-
tion rather than vorinostat. The disease types in which a benefit
was observed, including breast (one), melanoma (two), prostate
(one), were similar to those seen in the trial evaluating VPA and
epirubicin (Munster et al, 2007).
Pharmacodynamic and correlative studies
Preclinical studies suggest that a 48-h exposure to an HDAC
inhibitor will induce chromatin decondensation and modulation
of topo targets. The pharmacokinetic studies were limited and
directed towards defining the vorinostat dose levels at time of
doxorubicin exposure and correlating them with the effects on
deacetylase inhibitor targets. Vorinostat plasma levels were
obtained on day 3 at the time of the tumour biopsy and after a
3- to 4-h time interval after the last vorinostat dose. Vorinostat
plasma levels showed a significant increase (n¼ 32, P¼ 0.006) with
dose, albeit with wide interpatient variability (Figure 1A). The
median vorinostat dose of the 18 patients treated with the maximal
tolerated dose of 800mg day1 was 174.6±30.7 ngml1 and
equalled 0.66±0.12mM, similar to concentrations (0.5–1 mM)
required for in vitro synergy (Marchion et al, 2004).
Although vorinostat dose and levels were correlated, neither
histone H4 nor H3 acetylation in PBMCs was correlated with
vorinostat dose or vorinostat plasma level (Figure 1B and C). Of
the four patients with a response or a clinical benefit of 46
Table 3 Grades 3 and 4 toxicities (all cycles)
Toxicity Dose escalation
Dose
expansion
Dose (n) 400 (3) 600 (3) 800 (6) 1000 (6) 800 (12)
Neutropenia 1 1 1 2 3
Thrombocytopenia 0 0 1 1 1
Anemia 0 1 0 0 0
Lymphopenia 0 0 0 0 2
Fatigue 0 0 0 1 0
Elevated liver enzymes 0 0 0 0 1
Dehydration 1 0 0 0 0
Nausea/vomiting 1 0 0 1 0
Syncope 0 0 0 1 0
Pulmonary emboli 1 0 1 1 1
0
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Figure 1 Scatter diagrams of day 3 vorinostat dose, plasma levels, and histone acetylation. (A) Vorinostat (Vor) plasma levels in response to various doses
(mg day1). (B) Change in H4 histone acetylation by western blot at different vorinostat doses. (C) Change in H4 histone acetylation at different vorinostat
plasma levels. Closed diamonds (~) depict patients with objective response or clinical benefit (46 months). (D) Vorinostat plasma levels at different doses
for patients with grade 0 and 1 (}) or grade 2 and 3 fatigue (K).
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months, three patients showed high histone acetylation. The fourth
patient did not have sufficient PBMCs collected for analysis. The
patient with a 5.9-fold increase in acetyl-H4 was not evaluable for
response. As reported above, grade 2 or greater fatigue was seen in
450% of the patients. Fatigue was not correlated with dose or
vorinostat plasma levels obtained in cycle one (Figure 1D and data
not shown).
Vorinostat affects several HDAC enzyme targets, and preclinical
and clinical data with VPA have suggested that HDAC2 may be one
of the most relevant targets and its expression may be associated
with the degree of H4 acetylation (Marchion et al, 2009).
Vorinostat, a hydroxamic acid-type HDAC inhibitor, also affects
HDAC6, which is a distinguishing factor between selective and
non-selective HDAC inhibitors. We found that baseline expression
of HDAC2 but not HDAC6 was associated with increased
acetylation of histone H4 (Figure 2A and B). Several investigators
have reported a decrease in HDAC2 expression during exposure to
HDAC inhibitors; in this study, we did not find any changes in pre-
and post-treatment HDAC2 expression (median change in HDAC2:
þ 4% (95% confidence interval: 8 to þ 20% in PBMCs)).
Preclinical studies have suggested that exposure of cells to an
HDAC inhibitor is associated with histone hyperacetylation and
subsequent chromatin decondensation. The change in chromatin
plasticity is associated with a depletion of chromatin remodelling
proteins such as HP-1, structural maintenance of chromatin
proteins (SMC1-5), and DNA methyltransferase 1 (Marchion et al,
2005b). Furthermore, depletion of topo IIa has been associated
with chromatin decondensation (Adachi et al, 1991; Grue et al,
1998; Durrieu et al, 2000; Cuvier and Hirano, 2003; Marchion et al,
2005b).
Pre- and post-vorinostat PBMC samples were obtained in all
patients, but tumour biopsies were obtained in the 12 patients
treated at the dose expansion cohort. The average increase in H3
and H4 acetylation induced by vorinostat was comparable in
tumours and PBMCs (Figure 3A). The effects were further
comparable with histone acetylation seen in cultured MCF-7 cells
treated with 1 mM vorinostat for 48 h. Induction of tumour H4
acetylation was observed in 8 out of 12 patients (Figure 3B).
Vorinostat effects on downstream targets associated with chroma-
tin decondensation, depicted as depletion of HP-1 and topo IIa
expression, were observed in 8 out of 12 (66%) and 10 out of 12
patients (83%) respectively (Figure 3C).
DISCUSSION
Although HDAC inhibitors have shown efficacy in haematological
malignancies (Marshall et al, 2002; Sandor et al, 2002; Byrd et al,
2005; Kelly et al, 2005; Garcia-Manero et al, 2008), their single-
agent activity in solid tumours has been limited (Reid et al, 2004;
Luu et al, 2006; Stadler et al, 2006; Blumenschein et al, 2008). This
study describes a sequenced combination with the HDAC inhibitor
vorinostat given for 48 h followed by an anthracycline-type topo II
inhibitor, doxorubicin (Table 1). This sequence was based on cell
culture, in vivo models, and a previous phase I clinical trial
evaluating the HDAC inhibitor VPA in combination with
epirubicin (Munster et al, 2007). Preclinical models had shown
that HDAC inhibitor-induced histone hyperacetylation and
chromatin decondensation correlated with increased binding of
topo II inhibitors to the DNA substrate. In vitro data also
suggested that histone acetylation was necessary but not sufficient
for chromatin decondensation and required HDAC inhibitor-
induced depletion of chromatin remodelling proteins. HDAC
inhibitor treatment was further associated with topo IIa depletion
and recruitment of topo IIb (Marchion et al, 2004, 2005a, b, c).
The HDAC inhibitor used in this study is a hydroxamic-type
HDAC inhibitor with broader effects on HDAC enzymes, including
Class IIB and higher potency than VPA. The approved dose of
vorinostat (as a single agent) is 400mg day1, which is used in
most studies (Kelly et al, 2005). Higher doses have been explored,
but the cumulative toxicities, which include thrombocytopenia,
nausea, vomiting, anorexia, and fatigue, limit higher doses when
given daily for prolonged periods. In this study, we used vorinostat
to increase the efficacy of topo II inhibitors. Hence, the tolerability
of higher drug exposure, but at a shorter interval, was explored.
A weekly doxorubicin dosing was employed with the intent to
maximise exposure to vorinostat. We show that, when given for 3
days before a weekly administration of doxorubicin (20mgm2)
for 3 of 4 weeks, the maximum tolerated dose, as well as
recommended phase II dose for the combination, was 800mg
(400mg twice daily for five doses) in patients with advanced solid
tumour malignancies and a median of 2 before treatment regimens
for metastatic disease (Tables 1–3), which is higher than the
single-agent recommended dose. Fatigue (grade 2 and higher) was
seen in more than 50% of the patients beyond cycle 1 and was also
seen when doxorubicin was stopped. All reported toxicities
resolved rapidly after discontinuation of vorinostat. The observed
fatigue was not correlated with vorinostat doses or plasma level,
and no association was seen between histone acetylation in PBMC
and fatigue (Figure 1D and data not shown). Thromboembolic
events, pulmonary emboli in all four patients, occurred more
frequently than expected. Although thromboembolic events have
been associated with anthracyclines and cancer, the risk associated
with vorinostat is still under investigation and will require
randomized trials to determine the true incidence. Anticoagulation
should be considered in patients at risk.
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Figure 2 Correlation of Histone deacetylase (HDAC) 2 and HDAC6 expression with histone acetylation. Scatter plot of relative baseline protein
expression of HDAC2 (A, closed circles) and HDAC6 (B, open circles) plotted against change (x-fold increase) in histone acetylation. HDAC2 (P¼ 0.0006)
but not HDAC6 (P¼ 0.75) was positively correlated with a change in histone H4 acetylation.
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In this trial, 24 patients were evaluable for efficacy. Of these, two
patients had a partial response and two patients had stable disease
beyond 6 months. All four of these patients progressed once the
doxorubicin was stopped, suggesting the benefit was more likely
associated with the combination rather than with vorinostat. The
benefits seen in the patients with breast and prostate cancer may
be attributed to the anthracycline alone; however, melanoma is not
an anthracycline-sensitive disease (Lopez et al, 1984; Rosenthal
et al, 1998). Only testing in randomized trials will be able to
determine how much benefit the HDAC inhibitors contribute. The
number of patients is small on this trial; however, those patients
with a response or benefit have higher levels of histone acetylation
irrespective of vorinostat plasma levels or dose (Figure 1B and C).
The patient population with benefit from this therapy was similar
to those seen with the initial proof of principal study involving
VPA and epirubicin (Munster et al, 2007, 2009). Several patients
(7 out of 32) withdrew consent after one cycle in this study, which
is not uncommon in patients treated with multiple regimens;
however, it may also suggest that the toxicities, although not dose
limiting or grade 3 by CTCAE criteria, may be unacceptable to
patients. In particular, fatigue has been commonly described in
vorinostat trials. Fatigue and nausea were more common with
vorinostat, whereas somnolence and neurovestibular symptoms
were more commonly associated with VPA. Although the VPA-
induced somnolence was troubling to many patients, the every
3-week administration may have rendered these short-lived
toxicities more acceptable and did not lead to withdrawal
of patients from the study. Emerging data suggest that differential
inhibition of select HDAC enzymes is required for efficacy
among different tissues, and much emphasis has been placed on
developing selective HDAC inhibitors to improve efficacy.
However, given the varying toxicities between VPA and vorinostat,
the development of select HDAC inhibitors may also
allow minimisation or narrowing of toxicities seen with the
non-selective drugs.
One of the issues in monitoring the efficacy of HDAC inhibitors
has been determining the most appropriate surrogate marker for
monitoring the molecular effects of these agents. Furthermore,
there are limited data on downstream or other on-target effects of
vorinostat in solid tumour malignancies. Experimental data from
cell culture and xenograft data have suggested that histone
acetylation may occur as early as 30min after exposure, and the
depletion of chromatin remodelling genes and chromatin decon-
densation required a prolonged exposure (at least 24–48 h) to an
HDAC inhibitor. Furthermore, our preclinical study showed
synergistic interactions between HDAC and topo inhibitors in
the setting of HDAC inhibitor-induced depletion of topo IIa
(Marchion et al, 2005c). In addition to the vorinostat-induced
effects on H3 and H4 acetylation in PBMCs and tumour cells, we
examined effects on a representative of chromatin remodelling
proteins (HP-1) and topo IIa. We found that HP-1 levels, which
were assessed by immunofluorescence, were decreased in 8 out of
12 and topo IIa levels in 10 out of 12 patients treated at the
maximum tolerated dose, whereas histone H4 acetylation was
increased in 8 out of 12 patients, mirroring preclinical in vitro and
in vivo data.
There has been much emphasis on the distinction of selective vs
non-selective drugs and whether selectiveness will infer efficacy.
We have shown that, for chromatin remodelling, inhibition of
HDAC2 is crucial (Marchion et al, 2009). In addition to these
findings in vitro, we show in this study that pre-treatment
expression of HDAC2 can predict histone hyperactelyation. These
findings suggest that HDAC2 may be useful both as a response
prediction biomarker and as a target for the development of
isotype-specific inhibitors that could potentially achieve even
higher-level inhibition without the toxicity seen in current
generation compounds.
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Figure 3 Changes in histone acetylation, heterochromatin protein 1
(HP-1), and topoisomerase (topo) IIa expression in tumours and peripheral
blood mononuclear cells (PBMCs). (A) Bar graph of average change in
histone H4 and H3 acetylation in cultured MCF-7 cells (1mM vorinostat),
patient-derived PBMCs, and tumour cells (s.e. bars: confidence intervals) by
immunofluorescence. (B) Increase in acetylated histone H4 and
(C) decrease in HP-1 and topo IIa expression in individual patients
(1–12) treated at the dose expansion level by immunofluorescence.
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